Terns Pharmaceuticals, Inc.

TERN-101

non-alcoholic steatohepatitis (NASH)

Phase I trial initiated

OnKure, Inc.

OKI-179

advanced solid tumors

Phase I trial initiated

Purdue Pharma, L.P.

nalmefene hydrochloride (HCl)

opioid overdose

Phase I trial initiated

Goldfinch Bio, Inc.

GFB-887

kidney disease

Phase I trial initiated

Aerpio Pharmaceuticals, Inc.

AKB-9778

primary open angle glaucoma (POAG)

Phase Ib trial initiated enrolling 48 subjects

Adocia

ADO09

type 1 diabetes

Phase Ib trial initiated enrolling 24 subjects in Germany

Tolero Pharmaceuticals, Inc.

TP-0903

previously treated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)

Phase I/II trial initiated

Pharming Group N.V.

RUCONEST recombinant human C1 esterase inhibitor (rhC1INH)

pre-eclampsia

Phase I/II trial initiated

Noveome Biotherapeutics, Inc.

ST266

persistent corneal epithelial defects (PEDs)

Phase II trial initiated

Ivenix, Inc.

Ivenix Infusion System

infusion

510(k) clearance granted by the FDA

CorMatrix Cardiovascular, Inc.

Cor PATCH

cardiovascular disease

510(k) clearance granted by the FDA

Bolder Biotechnology, Inc.

BBT-059

Acute Radiation Syndrome (ARS)

Orphan Drug designation granted by the FDA

Palatin Technologies, Inc.

PL-8177

non-infectious intermediate, posterior, pan and chronic anterior uveitis

Orphan Drug designation granted by the FDA

Genentech

Rituxan (rituximab) in combination with glucocorticoids (GCC)

granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children two years of age and older

Priority Review granted by the FDA

SpeeDx Pty. Ltd.

ResistancePlus GC

N. gonorrhea

Breakthrough Device designation granted by the FDA

Xenikos B.V.

T-Guard

steroid-refractory acute graft-versus-host disease (SR-aGVHD)

IND approval granted by the FDA

Innovative Health Solutions, Inc.

IB-Stim

irritable bowel syndrome (IBS) in patients ages 11-18

Clearance granted by the FDA

Genentech

Polivy (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan (rituximab)

diffuse large B-cell lymphoma (DLBCL)

Accelerated approval granted by the FDA

Merck

KEYTRUDA

metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC)

Approval granted by the FDA

Senseonics Holdings, Inc.

Eversense Continuous Glucose Monitoring System

diabetes

Approval granted by the FDA